Protara Therapeutics, Inc. (TARA)
3.90
+0.04
(+1.04%)
USD |
NASDAQ |
Sep 01, 15:43
Protara Therapeutics Cash from Operations (Annual) : -56.36M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -56.36M |
| December 31, 2024 | -35.81M |
| December 31, 2023 | -37.56M |
| December 31, 2022 | -26.46M |
| December 31, 2021 | -34.50M |
| December 31, 2020 | -23.41M |
| December 31, 2019 | -5.011M |
| Date | Value |
|---|---|
| December 31, 2018 | -23.23M |
| December 31, 2017 | -22.35M |
| December 31, 2016 | -23.69M |
| December 31, 2015 | -17.57M |
| December 31, 2014 | -9.99M |
| December 31, 2013 | -6.703M |
| December 31, 2012 | -8.234M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| NovelStem International Corp. | -0.1676M |
| Brainstorm Cell Therapeutics, Inc. | -6.975M |
| Summit Therapeutics, Inc. | -322.93M |
| Kezar Life Sciences, Inc. | -51.78M |
| Clene, Inc. | -18.55M |